Keros Therapeutics, Inc.
KROS
$11.58
$0.110.96%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 3.04M | 388.00K | 37.00K | 83.00K | 143.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.04M | 388.00K | 37.00K | 83.00K | 143.00K |
| Cost of Revenue | -109.70M | 49.23M | 40.52M | 38.26M | -83.68M |
| Gross Profit | 112.75M | -48.84M | -40.48M | -38.18M | 83.83M |
| SG&A Expenses | 10.67M | 9.82M | 9.96M | 10.31M | 9.11M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 56.30M | 59.05M | 50.48M | 48.57M | 46.60M |
| Operating Income | -53.25M | -58.66M | -50.44M | -48.48M | -46.46M |
| Income Before Tax | -45.73M | -52.96M | -45.26M | -43.11M | -40.24M |
| Income Tax Expenses | 300.00K | -- | -- | -- | -- |
| Earnings from Continuing Operations | -46.03M | -52.96M | -45.26M | -43.11M | -40.24M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -46.03M | -52.96M | -45.26M | -43.11M | -40.24M |
| EBIT | -53.25M | -58.66M | -50.44M | -48.48M | -46.46M |
| EBITDA | -52.92M | -58.34M | -50.13M | -48.21M | -46.21M |
| EPS Basic | -1.14 | -1.41 | -1.25 | -1.21 | -1.34 |
| Normalized Basic EPS | -0.71 | -0.88 | -0.78 | -0.76 | -0.83 |
| EPS Diluted | -1.14 | -2.82 | -1.25 | -1.21 | -1.34 |
| Normalized Diluted EPS | -0.71 | -0.88 | -0.78 | -0.76 | -0.83 |
| Average Basic Shares Outstanding | 40.34M | 37.59M | 36.10M | 35.69M | 30.13M |
| Average Diluted Shares Outstanding | 40.34M | 37.59M | 36.10M | 35.69M | 30.13M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
